The “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma” was published in JITC September 12, 2021. SITC’s hepatocellular carcinoma expert panel developed this clinical practice guideline to cover important aspects of immunotherapeutic treatment for HCC, including diagnosis and staging, treatment planning, immune-related adverse events, and patient quality of life considerations.
The standard of care for HCC has been transformed as a combination of the immune checkpoint inhibitor (ICI) atezolizumab plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab was shown to offer improved overall survival in the first-line setting. Additional immunotherapies targeting the PD-(L)-1 axis are approved second-line options and ongoing trials are evaluating additional immunotherapeutic strategies for this disease state. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with HCC.
September 12, 2021